Literature DB >> 32382794

Inflammation, hippocampal volume, and cognition in schizophrenia: results from the Northern Finland Birth Cohort 1966.

Brian J Miller1, Karl-Heinz Herzig2,3,4, Jari Jokelainen3,5, Toni Karhu2, Sirkka Keinänen-Kiukaanniemi3,4,5, Marjo-Riitta Järvelin3,5,6,7, Juha Veijola3,8, Heimo Viinamäki7,9, Erika Jääskeläinen8, Matti Isohanni5, Markku Timonen5.   

Abstract

Increased blood interleukin-6 (IL-6) levels are a replicated abnormality in schizophrenia, and may be associated with smaller hippocampal volumes and greater cognitive impairment. These findings have not been investigated in a population-based birth cohort. The general population Northern Finland Birth Cohort 1966 was followed until age 43. Subjects with schizophrenia were identified through the national Finnish Care Register. Blood IL-6 levels were measured in n = 82 subjects with schizophrenia and n = 5373 controls at age 31. Additionally, 31 patients with schizophrenia and 63 healthy controls underwent brain structural MRI at age 34, and cognitive testing at ages 34 and 43. Patients with schizophrenia had significantly higher median (interquartile range) blood IL-6 levels than controls (5.31, 0.85-17.20, versus 2.42, 0.54-9.36, p = 0.02) after controlling for potential confounding factors. In both schizophrenia and controls, higher blood IL-6 levels were predictors of smaller hippocampal volumes, but not cognitive performance at age 34. We found evidence for increased IL-6 levels in patients with midlife schizophrenia from a population-based birth cohort, and replicated associations between IL-6 levels and hippocampal volumes. Our results complement and extend the previous findings, providing additional evidence that IL-6 may play a role in the pathophysiology of schizophrenia and associated brain alterations.

Entities:  

Keywords:  Birth cohort; Cognition; Hippocampus; Interleukin-6; Schizophrenia

Mesh:

Substances:

Year:  2020        PMID: 32382794     DOI: 10.1007/s00406-020-01134-x

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  85 in total

Review 1.  Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.

Authors:  Masahiro Nitta; Taishiro Kishimoto; Norbert Müller; Mark Weiser; Michael Davidson; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2013-05-29       Impact factor: 9.306

2.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

3.  Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.

Authors:  Wijnand Laan; Diederick E Grobbee; Jean-Paul Selten; Cobi J Heijnen; René S Kahn; Huibert Burger
Journal:  J Clin Psychiatry       Date:  2010-05       Impact factor: 4.384

4.  Meta-Analysis of Cytokine and Chemokine Genes in Schizophrenia.

Authors:  Zachary D Hudson; Brian J Miller
Journal:  Clin Schizophr Relat Psychoses       Date:  2016-07-25

5.  COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.

Authors:  Norbert Müller; Markus Ulmschneider; Constanze Scheppach; Markus J Schwarz; Manfred Ackenheil; Hans-Jürgen Möller; Rudolf Gruber; Michael Riedel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-02       Impact factor: 5.270

6.  Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.

Authors:  Iris E Sommer; Roos van Westrhenen; Marieke J H Begemann; Lot D de Witte; Stefan Leucht; René S Kahn
Journal:  Schizophr Bull       Date:  2013-10-08       Impact factor: 9.306

7.  Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms.

Authors:  Alexander Stojanovic; Lourdes Martorell; Itziar Montalvo; Laura Ortega; Rosa Monseny; Elisabet Vilella; Javier Labad
Journal:  Psychoneuroendocrinology       Date:  2013-12-14       Impact factor: 4.905

8.  Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia.

Authors:  R Zakharyan; M Petrek; A Arakelyan; F Mrazek; S Atshemyan; A Boyajyan
Journal:  Tissue Antigens       Date:  2012-05-10

9.  Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study.

Authors:  Golam M Khandaker; Rebecca M Pearson; Stanley Zammit; Glyn Lewis; Peter B Jones
Journal:  JAMA Psychiatry       Date:  2014-10       Impact factor: 21.596

10.  Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort.

Authors:  Golam M Khandaker; Stanley Zammit; Stephen Burgess; Glyn Lewis; Peter B Jones
Journal:  Brain Behav Immun       Date:  2017-12-02       Impact factor: 7.217

View more
  6 in total

1.  Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

2.  The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.

Authors:  M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

Review 3.  Structural and Functional Deviations of the Hippocampus in Schizophrenia and Schizophrenia Animal Models.

Authors:  David Wegrzyn; Georg Juckel; Andreas Faissner
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 4.  Longitudinal association between CRP levels and risk of psychosis: a meta-analysis of population-based cohort studies.

Authors:  Emanuele F Osimo; Luke Baxter; Jan Stochl; Benjamin I Perry; Stephen A Metcalf; Setor K Kunutsor; Jari A Laukkanen; Marie Kim Wium-Andersen; Peter B Jones; Golam M Khandaker
Journal:  NPJ Schizophr       Date:  2021-05-28

5.  Higher Dietary Inflammation in Patients with Schizophrenia: A Case-Control Study in Korea.

Authors:  Hee Yun Cha; Soo Jin Yang; Sung-Wan Kim
Journal:  Nutrients       Date:  2021-06-13       Impact factor: 5.717

6.  The Role of Peripheral Inflammation in Clinical Outcome and Brain Imaging Abnormalities in Psychosis: A Systematic Review.

Authors:  Melisa Kose; Carmine M Pariante; Paola Dazzan; Valeria Mondelli
Journal:  Front Psychiatry       Date:  2021-02-19       Impact factor: 5.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.